These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11795071)

  • 1. Pathogenesis and treatment of cardiomyopathy.
    Fonarow GC
    Adv Intern Med; 2001; 47():1-45. PubMed ID: 11795071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the addition of a beta-blocker on left ventricular remodeling and prognosis in patients with dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitor.
    Hamada M; Hara Y; Ohtsuka T; Suzuki J; Saeki H; Ogimoto A; Shigematsu Y
    J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S5-10. PubMed ID: 12688389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Up to date in pharmacological treatment of dilated cardiomyopathy.
    Ginghina C; Teodorescu A; Stoian I; Serban M; Ghiorghiu I; Wohlfart K
    Rom J Intern Med; 2004; 42(1):3-13. PubMed ID: 15529591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart failure: recent advances in prevention and treatment.
    Fonarow GC
    Rev Cardiovasc Med; 2000; 1(1):25-33, 54. PubMed ID: 12457149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurohormonal antagonism in heart failure: what is the optimal strategy?
    Sackner-Bernstein JD; Hart D
    Mt Sinai J Med; 2004 Mar; 71(2):115-26. PubMed ID: 15029403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies.
    Siddiqui A; Kowey PR
    Curr Opin Cardiol; 2006 Sep; 21(5):517-25. PubMed ID: 16900017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current management of pediatric dilated cardiomyopathy.
    Silva JN; Canter CE
    Curr Opin Cardiol; 2010 Mar; 25(2):80-7. PubMed ID: 20019605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental options in the treatment of heart failure: the role of cytokine antagonism.
    Kalra D; Bozkurt B; Deswal A; Torre-Amione G; Mann DL
    Heart Fail Monit; 2001; 1(4):114-21. PubMed ID: 12634895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacological treatment of heart failure: are we looking at the sunset of the neurohormonal hypothesis.
    Porcu M
    Ital Heart J; 2002 Jul; 3(7):437-8. PubMed ID: 12189976
    [No Abstract]   [Full Text] [Related]  

  • 10. Are Angiotensin-converting enzyme inhibitors and beta-blockers ineffective in children with dilated cardiomyopathy and heart failure?
    Singh TP; Almond C
    J Am Coll Cardiol; 2010 Aug; 56(10):823; author reply 823-4. PubMed ID: 20797500
    [No Abstract]   [Full Text] [Related]  

  • 11. Strategies to attenuate pathological remodeling in heart failure.
    Eapen Z; Rogers JG
    Curr Opin Cardiol; 2009 May; 24(3):223-9. PubMed ID: 19318933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular basis for therapeutic choices in heart failure.
    Opie LH
    Circulation; 2004 Oct; 110(17):2559-61. PubMed ID: 15505109
    [No Abstract]   [Full Text] [Related]  

  • 14. Association of blood pressure and its evolving changes with the survival of patients with heart failure.
    Grigorian-Shamagian L; Gonzalez-JuAnatey JR; Vazquez R; Cinca J; Bayes-Genis A; Pascual D; Fernandez-Palomeque C; Bardaji A; Almendral J; Nieto V; Macaya C; Jimenez RP; de Luna AB;
    J Card Fail; 2008 Sep; 14(7):561-8. PubMed ID: 18722321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R; McMurray JJ
    Heart; 2005 May; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential novel pharmacological therapies for myocardial remodelling.
    Landmesser U; Wollert KC; Drexler H
    Cardiovasc Res; 2009 Feb; 81(3):519-27. PubMed ID: 19019834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
    Healey JS; Morillo CA; Connolly SJ
    Curr Opin Cardiol; 2005 Jan; 20(1):31-7. PubMed ID: 15596957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects].
    Gronda E; Mangiavacchi M; Andreuzzi B; Municinò A
    Ital Heart J Suppl; 2001 Dec; 2(12):1278-83. PubMed ID: 11838348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease.
    Vonder Muhll I; Liu P; Webb G
    Int J Cardiol; 2004 Dec; 97 Suppl 1():25-33. PubMed ID: 15590076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.